China National Pharmaceutical Group Co Ltd (Sinopharm) unveiled its inaugural 2022 Environmental, Social and Governance (ESG) Report during the Central Enterprises and Local State-Owned Enterprises' Social Responsibility Blue Book Series release event held in Beijing on Dec 22.

Sinopharm's 2022 ESG report [Photo/sinopharm.com]

The report focuses on three key themes: "Pragmatic Sinopharm — Guiding High-Quality New Development", "Green Sinopharm — Building a Green and Safe Homeland Together", and "Caring Sinopharm — Safeguarding the People's Good Life". It comprehensively showcases Sinopharm's contributions to the economy, society, and environment throughout the year of 2022. 

Through detailed discussions on "Comprehensively Deepening Reform" and "Empowering Rural Revitalization", as well as its performance in Sustainable Development Goals (SDG) initiatives, the report underscores Sinopharm's role as a central medical enterprise and highlights Sinopharm's active support of national strategies, enhancement of core competitiveness, and contribution to the construction of a safe, green, harmonious, and beautiful society. 

It also emphasizes Sinopharm's commitment to studying and implementing the spirit of the 20th CPC National Congress. Adhering to a benefit-oriented approach, Sinopharm has intensified efforts to improve quality and efficiency, achieving new heights in comprehensive strength and operational efficiency. Upholding the principles of "People First, Life First", Sinopharm has strengthened the stable production and supply of pharmaceuticals, securing the lifeline of health. 

By adhering to innovation-driven development, Sinopharm is accelerating the construction of a leading technology enterprise and nurturing and expanding high-quality development momentum. 

Embracing the concept of safe and low-carbon development, Sinopharm is deeply promoting energy conservation, carbon reduction, synergy, and efficiency enhancement, and building a solid environmental protection and safety production defense line. 

In the new journey ahead, Sinopharm will fully leverage its role in building a modern industrial system and constructing a new development pattern, contributing greater efforts to comprehensively build a socialist modern country and realize the great rejuvenation of the Chinese nation. 

With the release of the ESG report, Sinopharm aims to further integrate ESG practices into its corporate development strategies, governance frameworks, and operational management. By collaborating with stakeholders, partners, employees, and others, Sinopharm seeks to engage in high-level ESG practices, contributing to the coordinated development of the economy, environment, and society.

Ultimately, Sinopharm aspires to become a world-class pharmaceutical and health industry group, accelerating the construction of a modern pharmaceutical industry system, and making significant contributions to the high-quality development of the economy and society.